for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ginkgo Bioworks Holdings Inc

DNA.N

Latest Trade

12.06USD

Change

0.06(+0.50%)

Volume

630,745

Today's Range

11.45

 - 

12.30

52 Week Range

8.90

 - 

15.85

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Ginkgo Bioworks Reports Third Quarter 2021 Results

Nov 15 (Reuters) - Ginkgo Bioworks Holdings Inc <DNA.N>::GINKGO BIOWORKS REPORTS THIRD QUARTER 2021 RESULTS.Q3 REVENUE $77.6 MILLION VERSUS $13.3 MILLION.QTRLY LOSS PER SHARE $0.08.SEES TOTAL FOUNDRY REVENUE OF AT LEAST $100 MILLION FOR FY21, INCLUSIVE OF DOWNSTREAM VALUE SHARE AND SERVICES REVENUE.

Synlogic And Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine For The Treatment Of Homocystinuria

Nov 9 (Reuters) - Ginkgo Bioworks Holdings Inc <DNA.N>::SYNLOGIC AND GINKGO BIOWORKS ANNOUNCE INVESTIGATIONAL SYNTHETIC BIOTIC MEDICINE FOR THE TREATMENT OF HOMOCYSTINURIA.SYNLOGIC- COLLABORATION GENERATES CLINICAL CANDIDATE SYNB1353 USING SYNLOGIC'S PROPRIETARY SYNTHETIC BIOTIC PLATFORM AND GINKGO CODEBASE.SYNLOGIC - EXPECTS TO FILE IND APPLICATION WITH FDA FOR SYNB1353 AND BEGIN CLINICAL DEVELOPMENT IN 2022.

Selecta Biosciences And Ginkgo Bioworks Holdings Inc Announce Partnership To Advance Treatments For Orphan And Rare Diseases

Oct 26 (Reuters) - Ginkgo Bioworks Holdings Inc <DNA.N>::SELECTA BIOSCIENCES AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ADVANCE TREATMENTS FOR ORPHAN AND RARE DISEASES.SELECTA BIOSCIENCES - LEVERAGING GINKGO'S CELL PROGRAMMING PLATFORM & CO'S IMMTOR PLATFORM TO CREATE POTENTIALLY TRANSFORMATIVE ENZYMATIC THERAPIES.SELECTA BIOSCIENCES - GAINS RIGHTS TO DEVELOP, COMMERCIALIZE SELECT THERAPEUTIC ENZYMES FROM GINKGO'S ADVANCED ORGANISM ENGINEERING PLATFORM.SELECTA BIOSCIENCES - GINKGO IS ELIGIBLE TO EARN CLINICAL AND COMMERCIAL MILESTONE PAYMENTS OF UP TO $85M IN CASH.SELECTA BIOSCIENCES - GINKGO ELIGIBLE TO EARN UPFRONT RESEARCH & DEVELOPMENT FEES, MILESTONES, INCLUDING CERTAIN PAYMENTS IN FORM OF CO'S COMMON STOCK.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up